US Stock MarketDetailed Quotes

SNTI Senti Biosciences

Watchlist
  • 3.3257
  • -0.2243-6.32%
Close Mar 27 16:00 ET
  • 3.3500
  • +0.0243+0.73%
Post 16:49 ET
86.48MMarket Cap-0.28P/E (TTM)

About Senti Biosciences Company

Senti Biosciences, Inc. It was incorporated in Delaware on March 1, 2021. The company aims to design genetic circuits to improve the intelligence of cells and gene therapy to improve its effectiveness, accuracy and persistence in the treatment of a wide range of diseases that cannot be solved by traditional drugs. The company's synthetic biology platform uses ready-made chimeric antigen receptor natural killer cells and is equipped with these genetic circuit technologies for particularly challenging liquid and solid tumor indications. The company's leading projects include SENTI-202 and SENTI-301. SENTI-202 is a logic-gated or + non-ready-made CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells while preserving healthy bone marrow. SENTI-301 is an off-the-shelf CAR-NK cell therapy for the treatment of hepatocellular carcinoma. The company has also demonstrated the breadth of its genetic circuits in ways other than oncology and diseases, and has partnered with Spark and BlueRock to advance these capabilities.

Company Profile

SymbolSNTI
Company NameSenti Biosciences, Inc.
Listing DateMay 26, 2021
Founded2016
CEODr. Timothy Lu, M.D.,PhD
MarketNASDAQ
Employees34
Fiscal Year Ends12-31
Address2 Corporate Drive,First Floor
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-650-239-2030

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Timothy Lu, M.D.,PhD
  • Chief Executive Officer, President and Director
  • 1.69M
  • Jay Cross
  • Chief Financial Officer
  • --
  • Dr. Kanya Rajangam, M.D.,PhD
  • President, Head of Research and Development and Chief Medical Officer
  • 858.77K
  • Faraz Siddiqui
  • Senior Vice President, Technical Operations
  • --
  • Feng Hsiung
  • Director
  • --
  • Donald Tang
  • Director
  • --
  • Frances D. Schulz
  • Independent Director
  • --
  • Edward T. Mathers
  • Independent Director
  • 94.72K
  • Dr. James J. Collins, PhD
  • Independent Director
  • 107.70K
  • Dr. Brenda Cooperstone, M.D.
  • Independent Director
  • 94.22K

Market Insights

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.